Critical assessment of influenza VLP production in Sf9 and HEK293 expression systems

BMC Biotechnology

Volumn 15, Issue 1, 2015, Pages

  Thompson, Christine M ^a,b   Petiot, Emma ^a,c   Mullick, Alaka ^a   Aucoin, Marc G ^d   Henry, Olivier ^b   Kamen, Amine A ^a,e  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b ÉCOLE POLYTECHNIQUE DE MONTRÉAL   (Canada)

^c UNIVERSITÉ DE LYON   (France)

^d UNIVERSITY OF WATERLOO   (Canada)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

Influenza vaccines; Insect cells; Mammalian cells; Process development; Virus like particles (VLPs); VLP characterization

Indexed keywords

ANTIGEN-ANTIBODY REACTIONS; ANTIGENS; CELL CULTURE; CYTOLOGY; DISEASE CONTROL; MAMMALS; MANUFACTURE; TRANSMISSION ELECTRON MICROSCOPY; VACCINES; VIRUSES;

INFLUENZA VACCINES; INSECT CELLS; MAMMALIAN CELLS; PROCESS DEVELOPMENT; VIRUS-LIKE PARTICLES;

CELLS;

INFLUENZA VACCINE; MATRIX PROTEIN; VIRUS HEMAGGLUTININ; VIRUS SIALIDASE; M1 PROTEIN, INFLUENZA A VIRUS; NA PROTEIN, INFLUENZA A VIRUS; SIALIDASE; VIRAL PROTEIN; VIRUS ANTIGEN;

ANIMAL CELL; ARTICLE; BACULOVIRUS EXPRESSION SYSTEM; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; DRUG DESIGN; DRUG PURITY; DRUG SYNTHESIS; HEK293 CELL LINE; HUMAN; HUMAN CELL; IMMUNODIFFUSION; INFLUENZA; INFLUENZA VIRUS; INSECT CELL; NEGATIVE STAINING TRANSMISSION ELECTRON MICROSCOPY; NONHUMAN; PROTEIN ANALYSIS; SF9 CELL LINE; TRANSMISSION ELECTRON MICROSCOPY; VIRUS LIKE AGENT; WESTERN BLOTTING; ANIMAL; CHEMISTRY; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; VIRION;

HEXAPODA; MAMMALIA; ORTHOMYXOVIRIDAE;

ANIMALS; ANTIGENS, VIRAL; HEK293 CELLS; HUMANS; INFLUENZA VACCINES; NEURAMINIDASE; SF9 CELLS; VIRAL MATRIX PROTEINS; VIRAL PROTEINS; VIRION;

EID: 84929318605     PISSN: None     EISSN: 14726750     Source Type: Journal    
DOI: 10.1186/s12896-015-0152-x     Document Type: Article

References (49)

1. World Health Organization (WHO). Influenza (Seasonal) fact sheet. In: WHO media cent. 2014.
2. Cohen J. Out of Mexico? Scientists ponder swine flu's origins. Science. 2009;324:700-3.
3. Michaelis M, Doerr HW, Cinatl J. Novel swine-origin influenza A virus in humans: another pandemic knocking at the door. Med Microbiol Immunol. 2009;198:175-83.
4. Gerdil C. The annual production cycle for influenza vaccine. Vaccine. 2003;21:1776-9.
5. Johnson TD. Next generation of flu vaccines comming of age: cell-based technology may replace egg-based flu vaccines. Nations Health. 2010;40:1-27.
6. Haynes JR. Influenza virus-like particle vaccines. Expert Rev Vaccines. 2009;8:435-45.
7. Kang S-M, Song J-M, Quan F-S, Compans RW. Influenza vaccines based on virus-like particles. Virus Res. 2009;143:140-6.
8. Pushko P, Tumpey TM, Bu F, Knell J, Robinson R, Smith G. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine. 2005;23:5751-9.
9. Wu C-Y, Yeh Y-C, Yang Y-C, Chou C, Liu M-T, Wu H-S, et al. Mammalian expression of virus-like particles for advanced mimicry of authentic influenza virus. PLoS One. 2010;5, e9784.
10. Quan F-S, Vunnava A, Compans RW, Kang S-M. Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice. PLoS One. 2010;5, e9161.
11. Kang S-M, Yoo D-G, Lipatov AS, Song J-M, Davis CT, Quan F-S, et al. Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS One. 2009;4, e4667.
12. Latham T, Galarza JM. Formation of Wild-Type and Chimeric Influenza Virus-Like Particles following Simultaneous Expression of Only Four Structural Proteins. Journal of Virology. 2001;75(3):6154-65.
13. Pushko P, Pearce MB, Ahmad A, Tretyakova I, Smith G, Belser JA, et al. Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes. Vaccine. 2011;29:5911-8.
14. Smith GE, Flyer DC, Raghunandan R, Liu Y, Wei Z, Wu Y, et al. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus. Vaccine. 2013;31:4305-13.
15. Landry N, Ward BJ, Trépanier S, Montomoli E, Dargis M, Lapini G, et al. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS One. 2010;5, e15559.
16. López-Macías C, Ferat-Osorio E, Tenorio-Calvo A, Isibasi A, Talavera J, Arteaga-Ruiz O, et al. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico. Vaccine. 2011;29:7826-34.
17. D'Aoust M-A, Couture MM-J, Charland N, Trépanier S, Landry N, Ors F, et al. The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. Plant Biotechnol J. 2010;8:607-19.
18. Krammer F, Schinko T, Palmberger D, Tauer C, Messner P, Grabherr R. Trichoplusia ni cells (High Five) are highly efficient for the production of influenza A virus-like particles: a comparison of two insect cell lines as production platforms for influenza vaccines. Mol Biotechnol. 2010;45:226-34.
19. Tang X-C, Lu H-R, Ross TM. Baculovirus-produced influenza virus-like particles in mammalian cells protect mice from lethal influenza challenge. Viral Immunol. 2011;24:311-9.
20. Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine. 2007;25:3871-8.
21. Quan F-S, Huang C, Compans RW, Kang S-M. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol. 2007;81:3514-24.
22. Margine I, Martinez-Gil L, Chou Y, Krammer F. Residual baculovirus in insect cell-derived influenza virus-like particle preparations enhances immunogenicity. PLoS One. 2012;7, e51559.
23. Cox MMJ, Hollister JR. FluBlok, a next generation influenza vaccine manufactured in insect cells. Biologicals. 2009;37:182-9.
24. Liu F, Wu X, Li L, Liu Z, Wang Z. Use of baculovirus expression system for generation of virus-like particles: successes and challenges. Protein Expr Purif. 2013;90:104-16.
25. Chen BJ, Leser GP, Morita E, Lamb RA. Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles. J Virol. 2007;81:7111-23.
26. Vicente T, Roldão A, Peixoto C, Carrondo MJT, Alves PM. Large-scale production and purification of VLP-based vaccines. J Invertebr Pathol. 2011;107(Suppl):S42-8.
27. Côté J, Garnier A, Massie B, Kamen A, Cote J. Serum-free production of recombinant proteins and adenoviral vectors by 293SF-3 F6 cells. Biotechnol Bioeng. 1998;59:567-75.
28. Petiot E, Jacob D, Lanthier S, Lohr V, Ansorge S, Kamen AA. Metabolic and kinetic analyses of influenza production in perfusion HEK293 cell culture. BMC Biotechnol. 2011;11:1-12.
29. Alain R, Nadon F, Séguin C, Payment P, Trudel M. Rapid virus subunit visualization by direct sedimentation of samples on electron microscope grids. J Virol Methods. 1987;16:209-16.
30. Le Ru A, Jacob D, Transfiguracion J, Ansorge S, Henry O, Kamen AA. Scalable production of influenza virus in HEK-293 cells for efficient vaccine manufacturing. Vaccine. 2010;28:3661-71.
31. Moulès V, Terrier O, Yver M, Riteau B, Moriscot C, Ferraris O, et al. Importance of viral genomic composition in modulating glycoprotein content on the surface of influenza virus particles. Virology. 2011;414:51-62.
32. Roberts PC, Lamb RA, Compans RW. The M1 and M2 proteins of influenza A virus are important determinants in filamentous particle formation. Virology. 1998;240:127-37.
33. Calder LJ, Wasilewski S, Berriman JA, Rosenthal PB. Structural organization of a filamentous influenza A virus. Proc Natl Acad Sci U S A. 2010;107:10685-90.
34. Elleman CJ, Barclay WS. The M1 matrix protein controls the filamentous phenotype of influenza A virus. Virology. 2004;321:144-53.
35. McCown MF, Pekosz A. Distinct domains of the influenza a virus M2 protein cytoplasmic tail mediate binding to the M1 protein and facilitate infectious virus production. J Virol. 2006;80:8178-89.
36. Bialas KM, Bussey KA, Stone RL, Takimoto T. Specific nucleoprotein residues affect influenza virus morphology. J Virol. 2014;88:2227-34.
37. Chen BJ, Leser GP, Jackson D, Lamb RA. The influenza virus M2 protein cytoplasmic tail interacts with the M1 protein and influences virus assembly at the site of virus budding. J Virol. 2008;82:10059-70.
38. Watanabe K, Shimizu T, Noda S, Tsukahara F, Maru Y, Kobayashi N. Nuclear export of the influenza virus ribonucleoprotein complex: Interaction of Hsc70 with viral proteins M1 and NS2. FEBS Open Bio. 2014;4:683-8.
39. Shaw ML, Stone KL, Colangelo CM, Gulcicek EE, Palese P. Cellular proteins in influenza virus particles. PLoS Pathog. 2008;4, e1000085.
40. Lai JCC, Chan WWL, Kien FF, Nicholls JM, Peiris JSM, Garcia J-M. Formation of virus-like particles from human cell lines exclusively expressing influenza neuraminidase. J Gen Virol. 2010;91(Pt 9):2022-30.
41. Gómez-Puertas P, Mena I, Castillo M, Vivo A, Pérez-Pastrana E, Portela A. Efficient formation of influenza virus-like particles: dependence on the expression levels of viral proteins. J Gen Virol. 1999;80(Pt 7):1635-45.
42. Thompson C, Petiot E, Lennaertz A, Henry O, Kamen A. Analytical technologies for influenza virus-like particle candidate vaccines: challenges and emerging approaches. Virology Journal. 2013;10:141; 14 pages (open access).
43. Valle JR, Cha S, Medina F, Angel RM. Heat shock protein 90 and heat shock protein 70 are components of dengue virus receptor complex in human cells. Society. 2005;79:4557-67.
44. Rossman JS, Lamb RA. Influenza virus assembly and budding. Virology. 2011;411:229-36.
45. Welsch S, Müller B, Kräusslich H-G. More than one door - Budding of enveloped viruses through cellular membranes. FEBS Lett. 2007;581:2089-97.
46. Haynes JR, Dokken L, Wiley J, Cawthon AG, Bigger J, Harmsen AG, et al. Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge. Vaccine. 2009;27:530-41.
47. Denzer K, Kleijmeer MJ, Heijnen HF, Stoorvogel W, Geuze HJ. Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci. 2000;113(Pt 19):3365-74.
48. Hervas-Stubbs S, Rueda P, Lopez L, Leclerc C. Insect baculoviruses strongly potentiate adaptive immune responses by inducing type I IFN. J Immunol. 2007;178:2361-9.
49. Molinari P, Crespo MI, Gravisaco MJ, Taboga O, Morón G. Baculovirus capsid display potentiates OVA cytotoxic and innate immune responses. PLoS One. 2011;6, e24108.